Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Nov 27, 2024; 16(11): 3463-3470
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3463
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3463
Table 1 Comparison of patients’ baseline data before matching, n (%)
| Variable | Group A (n = 125) | Group B (n = 106) | χ2/t | P value |
| Sex | 0.392 | 0.531 | ||
| Male | 77 (61.60) | 61 (57.55) | ||
| Female | 48 (38.40) | 45 (42.45) | ||
| Age (years), mean ± SD | 54.84 ± 7.95 | 54.07 ± 9.99 | 0.656 | 0.513 |
| Child-Pugh grading | 8.331 | 0.004 | ||
| Grade A | 78 (62.40) | 46 (43.40) | ||
| Grade B | 47 (37.60) | 60 (56.60) | ||
| TNM stage | 7.262 | 0.007 | ||
| Stage III | 81 (64.80) | 50 (47.17) | ||
| Stage IV | 44 (35.20) | 56 (52.83) | ||
| ECOG score (score) | 9.532 | 0.002 | ||
| 0-1 | 83 (66.40) | 49 (46.23) | ||
| 2 | 42 (33.60) | 57 (53.77) |
Table 2 Comparison of patients’ baseline data after matching, n (%)
| Variable | Group A (n = 86) | Group B (n = 86) | χ2/t | P value |
| Sex | 0.214 | 0.643 | ||
| Male | 51 (59.30) | 48 (55.81) | ||
| Female | 35 (40.70) | 38 (44.19) | ||
| Age (years), mean ± SD | 54.36 ± 8.37 | 53.84 ± 8.45 | 0.408 | 0.684 |
| Child-Pugh grading | 8.331 | 0.004 | ||
| Grade A | 44 (51.12) | 44 (51.12) | 0.000 | 1.000 |
| Grade B | 42 (48.84) | 42 (48.84) | ||
| TNM stage | 0.023 | 0.879 | ||
| Stage III | 46 (53.49) | 45 (52.33) | ||
| Stage IV | 40 (46.51) | 41 (47.67) | ||
| ECOG score (score) | 0.024 | 0.878 | ||
| 0-1 | 48 (55.81) | 49 (56.98) | ||
| 2 | 38 (44.19) | 37 (43.02) |
Table 3 Comparison of treatment effect between the two groups, n (%)
| Group | CR | PR | SD | PD | ORR | DCR |
| Group A (n = 86) | 34 (39.53) | 35 (40.70) | 15 (17.44) | 2 (2.33) | 69 (80.23) | 84 (97.67) |
| Group B (n = 86) | 27 (31.40) | 25 (29.07) | 24 (27.91) | 11 (12.79) | 52 (60.47) | 75 (87.21) |
| χ2 | 8.055 | 6.740 | ||||
| P value | 0.005 | 0.009 |
Table 4 Comparison of the total incidence of adverse reactions in groups A and B, n (%)
| Group | Nausea and vomiting | Diarrhea | Fever | Leukopenia | Total incidence (%) |
| Group A (n = 86) | 2 (2.33) | 1 (1.16) | 1 (1.16) | 2 (2.33) | 6 (6.97) |
| Group B (n = 86) | 5 (5.81) | 5 (5.81) | 3 (3.49) | 6 (6.97) | 19 (22.09) |
| χ2 | 6.287 | ||||
| P value | 0.012 |
- Citation: Cheng XB, Yang L, Lu MQ, Peng YB, Wang L, Zhu SM, Hu ZW, Wang ZL, Yang Q. Clinical study of different interventional treatments for primary hepatocellular carcinoma based on propensity-score matching. World J Gastrointest Surg 2024; 16(11): 3463-3470
- URL: https://www.wjgnet.com/1948-9366/full/v16/i11/3463.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i11.3463